Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Winsantor Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, creating a decentralized prosecution environment where each examiner is responsible for a single case. Both matters are situated within 1 distinct art unit, which provides a consistent technical and procedural baseline for the company's patent efforts in this sector.
Andrew D Kosar is identified as the busiest examiner for this portfolio, with 1 pending office action under his review. Because there are 2 distinct examiners for 2 pending office actions, the company must navigate the individual preferences of multiple officials within the same 1 distinct art unit. This structure allows the applicant to compare examiner behaviors while remaining within the Biotechnology & Pharmaceuticals technology area. The concentration of 2 pending office actions in 1 distinct art unit suggests that while the examiners differ, the overarching examination policies and prior art references will likely remain consistent across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, ANDREW D | 1 | 42.0% | +31.8% |
| GONZALEZ, LUISALBERTO | 1 | 59.4% | +47.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17593792 | TOPICAL FORMULATIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | GONZALEZ, LUISALBERTO | 62d |
| 18767228 | COMPOSITIONS AND METHODS FOR IMPROVING SEXUAL SENSORY DISORDERS | KOSAR, ANDREW D | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18767228 | COMPOSITIONS AND METHODS FOR IMPROVING SEXUAL SENSORY DISORDERS | KOSAR, ANDREW D | — | §103§112DP | Non-Final OA | — | Pending | Jul 09, 2024 |
| 17593792 | TOPICAL FORMULATIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | GONZALEZ, LUISALBERTO | 1624 | §103 | Final Rejection | 62d | Pending | Sep 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial